Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

A recent Frontiers in Immunology journal study by University of North Carolina at Chapel Hill and Vanderbilt University researchers has created an in vitro system to determine potential therapeutics targeting sensitized effector cells based on human, allergen-specific, Immunoglobulin E (IgE) monoclonal antibodies (mAbs).

2 Oct 2022

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

In a recent study posted to the medRxiv* preprint server, researchers in the United States described the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tested in PREVENT-19 — a phase 3, randomized, placebo-controlled, observer-blinded trial among 12- to 17-year-old adolescents in the United States (U.S).

25 Sep 2022

The incidence rates of adverse events of special interest in COVID-19 vaccinated and non-vaccinated persons

Researchers monitored the safety of the four diverse SARS-CoV-2 vaccines approved by the EMA and MHRA in 2020 to 2021.

24 Aug 2022

Updated guidelines on the Valneva SARS-CoV-2 vaccine

The WHO provides interim guidelines for the use of the Valneva vaccine.

23 Aug 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Inappropriate antibiotic prescriptions for children associated with excess health-care costs

Antibiotics inappropriately prescribed to nonhospitalized children resulted in at least $74 million in excess health-care costs in the U.S. in 2017, according to a new study from Washington University School of Medicine in St. Louis and The Pew Charitable Trusts.

26 May 2022

Using microfluidics and magnets to isolate rare, allergen-reactive white blood cells

Across the world, food allergies are on the rise. One of the most important cells in studying this ailment are basophils, which activate inflammation and other responses to allergens such as rashes, and sometimes, anaphylaxis.

23 May 2022

Risk for anaphylaxis higher with two intravenous iron formulations

Two products commonly administered intravenously to replenish iron levels in the body have a much higher chance of provoking a severe allergic attack, according to Rutgers researchers who conducted a study analyzing the medical records in a large database of older, Medicare patients.

29 Mar 2022

Clinical trial shows encouraging results with fecal microbiota transplants for peanut-allergic patients

Peanut allergies are hard to treat and can cause fatal or near-fatal anaphylactic reactions. People usually don't outgrow peanut allergy, requiring lifelong scrutiny of food labels to avoid even small traces of peanut.

27 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Assessing potential allergic reactions in COVID-19 vaccinated patients

Researchers analyze suspected reactions in patients vaccinated with the first and/or second dose of SARS-CoV-2 vaccines.

13 Feb 2022

Two peanut allergy treatments for children found to be highly effective at inducing remission

Researchers have discovered two peanut allergy treatments for children that are both highly effective at inducing remission.

7 Feb 2022

Vaccine hypersensitivity in children

A new paper published in Pediatric Allergy and Immunity provides a useful overview of such reactions in relation to pediatric vaccines.

31 Jan 2022

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

The majority of young children treated with peanut immunotherapy achieved desensitization after two and a half years of treatment, and one in five remained in remission 26 weeks after treatment ended, according to a randomized controlled trial published in The Lancet.

20 Jan 2022

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

A growing body of evidence indicates that some people thought to have an allergic response to injectable penicillin, the standard treatment for rheumatic heart disease, may instead be experiencing a cardiac reaction to the medicine, according to a new American Heart Association presidential advisory published today in Journal of the American Heart Association.

19 Jan 2022

Anaphylaxis News and Research

Further Reading

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

The incidence rates of adverse events of special interest in COVID-19 vaccinated and non-vaccinated persons

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Inappropriate antibiotic prescriptions for children associated with excess health-care costs

Using microfluidics and magnets to isolate rare, allergen-reactive white blood cells

Risk for anaphylaxis higher with two intravenous iron formulations

Clinical trial shows encouraging results with fecal microbiota transplants for peanut-allergic patients

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Assessing potential allergic reactions in COVID-19 vaccinated patients

Two peanut allergy treatments for children found to be highly effective at inducing remission

Vaccine hypersensitivity in children

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

International approaches to tackling food fraud

Mathematical modeling the vaccination of children against SARS-CoV-2

Oral bacteria-based SARS-CoV-2 vaccine platform

Clear, specific product labeling for sesame is crucial to prevent anaphylaxis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News